Skip to main content
. 2022 Apr 8;76(4):1000–1012. doi: 10.1002/hep.32468

FIGURE 2.

FIGURE 2

Graphical representation of (A) the number of GI bleeding events in relationship with grade of varices at pretreatment EGD; (B) the number of bevacizumab‐related bleeding events across CP classes; (C) the number of atezolizumab‐related AEs across CP classes. [Correction statement added May 16, 2022 after first online publication: the values in the x‐axis were corrected in Figures 2B and 2C]